The effects of the anticholinesterases tetrahy droaminoacridine (THA) and physostigmine on local ce rebral glucose utilization (LCG U) were studied in the conscious rat, using the autoradiographic [14C]deoxyglu cose technique. THA (5 mg/kg i.p.) increased LCGU sig nificantly in 8 of the 43 regions studied. A higher dose of THA (10 mg/kg) produced a metabolic activation in 19 of the 43 regions. LeGU increased in cortical areas (indud ing parietal and temporal cortices), the septohippocampal system, the thalamus, the lateral habenula, the basolat era! amygdala, the superior colliculus, and the substantia nigra. Scopolamine (4 mg/kg i.p.) reversed the THA induced LeGU increase. Physostigmine (0.2 and 0.5 mg/ kg) increased LeGU in 15 and 22 regions, respectively. The average magnitude of the change induced by 0.5 mg/
Local cerebral glucose utilization (LCGU) is a reliable measure of local cerebral metabolism. De creased LCG U is a consistent finding in dementia of the Alzheimer type (especially in parietal and tem poral cortices) and correlates with the severity of cognitive impairment (Benson et aI., 1983; Fried land et aI., 1985; Duara et aI., 1986) .
Although deficits in several neurotransmitters oc cur in Alzheimer's disease, the involvement of the cholinergic system seems to be the most severe and the most consistent (Bowen et aI., 1985) . Clinical trials attempting to increase the synthesis of acetyl choline (ACh) by the administration of the ACh pre cursors choline or lecithin or to stimulate muscarin-kg of physostigmine was similar to that observed after THA at 10 mg/kg, but the topography of the effects was somewhat different. Physostigmine increased LeGU in the preoptic magnocellular area, the brainstem, and the cerebellum but not in the parietal cortex. The effects in the septohippocampal system were smaller than those in duced by THA. The regional topography of the LeGU increase overlapped the distribution of the M2 muscarinic receptors and that of acetylcholinesterase activity. These data suggest that the major effects of THA and physo stigmine on LCGU result from their anticholinesterase action. Key Words: Acetylcholine-Anticholinesterase Local cerebral glucose utilization-Physostigmine Tetrahydroaminoacridine.
ic receptors with specific agonists have met with little success (for review see Hallak and Giacobini, 1989) . Recently, inhibitors of acetylcholinesterase (AChE; the hydrolytic enzyme of ACh) have been used to increase cholinergic neurotransmission. The therapeutic effects of physostigmine are lim ited, particularly because of its short duration of action (Mohs et aI. , 1985; Zec, 1988) . More substan tial improvements have been observed in some Alz heimer patients receiving tetrahydroaminoacridine (THA), a centrally acting anticholinesterase. The initial positive results of Summers et ai. (1986) have been confirmed by several investigators (Eagger et aI. , 1991; Davis et aI., 1992; Farlow et aI., 1992) , while others reported mostly negative findings (Chatellier and Lacomblez, 1990; Gauthier et aI., 1990) . The reasons for the greater efficacy of THA in comparison with other cholinergic drugs are not clear. The effects of THA in the central nervous system are complex (for review see Freeman and Dawson, 1991) . In addition to an inhibitory effect on AChE, THA interacts with muscarinic and nic-otinic receptors (Perry et aI., 1988; Hunter et aI., 1989) and modulates the release of ACh (Nilsson et aI., 1987) . At relatively high concentrations, THA has also an effect on monoaminergic systems, by blocking monoamine release and uptake (Drukarch et aI., 1988) and by inhibiting the enzyme mono amine oxidase (Adem et aI., 1989) . Finally, a direct blocking action of THA on potassium and sodium channels has been reported (Rogawski, 1987; Stevens and Cotman, 1987; Halliwell and Grove, 1989; Dutar et aI., 1990) .
Only preliminary descriptions of the effects of physostigmine on cerebral metabolism are available (Holloway et aI., 1985; Scremin et aI., 1988) , and those of THA have not been studied so far in the experimental animal. One could hypothesize that the therapeutic effects of anticholinesterases in volve an effect on LCGU. The aim of the present work was to study the effects of THA and physo stigmine, a "reference" anticholinesterase, on LCG U in the rat.
MATERIALS AND METHODS

Animals
Male Sprague-Dawley rats (n = 36; Charles River, France) weighing 270--320 g were used. The rats were housed at 22°C under a 12-h light/dark cycle and had free access to water and food.
Chemicals
THA was obtained from Aldrich (U .S.A.). Physostig mine, scopolamine, hexamethonium bromide (HMB), and atropine methyl bromide (AMB) were obtained from Sigma (France). [14C]2-DeoxY-D-glucose ([14C]DG; spe cific activity 50--55 mCi/mmol) in ethanol was purchased from Amersham (France). The solution was evaporated under nitrogen and [14C]DG was resuspended in isotonic saline.
Measurement of LCGU
LCGU was measured by the quantitative [14C]DG tech nique of Solokoff et al. (1977) . Following 16 h of food deprivation, rats were lightly anesthetized (1 % halothane in oxygen) and catheters were inserted in a femoral vein and artery. The operative sites were infiltrated with 1 % xylocaine and closed with wound clips. A loose-fitting plaster cast was applied around the trunk and hindlimbs for restraint. This arrangement permitted free movements of head and forelimbs. Body temperature was monitored via a rectal thermoprobe connected to a thermostatic de vice (Harvard, U.K.), which activated an external warm ing element when body temperature fell below 35SC. Mean arterial blood pressure and heart rate were assessed before and at fixed times after drug treatment by connect ing the arterial catheter to a pressure transducer (Barovar; Alvar Electronic, France), which was attached to a paper chart recorder (Gould, U.S.A.). Baseline and subsequent measurements of plasma glucose concentra tion were made throughout the experiment (Glucose An alyzer II; Beckman, U.S.A.). Hematocrit was determined prior to the injection of [14C]DG. Animals were excluded J Cereb Blood Flow Metab. Vol. 13, No.5, 1993 from the study if baseline values were outside of the fol lowing limits: mean arterial pressure 90--1 30 mm Hg, tem perature 35-38°C, plasma glucose concentration 100--200 mg/dl. After a 4-h recovery period, [14C]DG 125 fJ-Ci/kg was administered by rapid intravenous bolus injection. Arte rial blood samples (100 fJ-1) were taken at 6, 18, and 30 s and 1, 3, 5, 7.5, 15, 25, 35 , and 45 min after [14C]DG injection. Samples were centrifuged immediately and plasma radioactivity (liquid scintillation counter 1209; LKB Wallac, U.S.A.) and glucose concentration were measured. Animals were killed 45 min after [14C]DG by an overdose of pentobarbital. Brains were removed rap idly and frozen in isopentane, chilled with dry ice at -45°C, and then stored at -70°C. Coronal brain sections 20 fJ-m thick were cut on a crysostat (Reichert-Jung; Cam bridge Instrument, Germany) at -20°C. Sections were mounted on coverslips and dried immediately at 55°C on a hot plate. Autoradiographs were then prepared by ex posing X-AR5 x-ray film (Kodak) to the mounted sections and [14C]methylmethacrylate standards (Amersham) for 7 days.
Autoradiograms were analyzed by quantitative densi tometry with a computerized image-processing device (Biocom, France). Optical density measurements for each structure, identified according to the brain atlas of Paxinos and Watson (1982) , were made in a minimum of four brain sections. Tissue 14C concentrations were de termined from the optical densities and a calibration curve obtained by a densitometric analysis of the autora diograms of the calibrated standards. LCGU was then calculated from the local tissue 14C concentrations, the time course of the plasma [14C]DG and glucose concen tration, and appropriate kinetic constants according to the operational equation published by Sokoloff et al. (1977) .
Drug treatments
LCGU was assessed in six groups of five rats. To block the peripheral effects of anticholinesterases, animals were pretreated with HMB (5 mg/kg i.p.) and AMB (4 mg/kg s.c.), respectively, 30 and 20 min before drug ad ministration, except in the control group (saline group), which received an equal volume of isotonic saline (i.p. and s.c.). Animals then received an intraperitoneal injec tion of isotonic saline (saline and HMB + AMB groups) or THA (5 or 10 mg/kg) or physostigmine (0.2 or 0.5 mgl kg). Physostigmine and THA were, respectively, injected 10 and 50 min before e4C]DG (see Time Course of Drug Effects). In addition, two groups of three rats received the central anticholinergic scopolamine hydrobromide (2 or 4 mg/kg i.p.) 15 min before the injection of THA (10 mg/kg) to verify that the effects of THA on LCGU were blocked by a muscarinic antagonist.
Statistical analysis
Physiological variables and LCGU values from control and treated rats were compared by one-way analysis of variance, followed by Scheffe's test. Differences were considered significant if p < 0.05.
RESULTS
Time course of drug effects
To inject the e4C]DG at the peak of the drugs' effects, a pilot experiment was performed to deter-mine the time course of the behavioral effects of both drugs. Rats (five animals per dose) received an intraperitoneal injection of THA (3, 5, or 10 mg/kg) or of physostigmine (0.2 or 0.5 mg/kg). Control rats (five animals) received an equal volume of saline. Central body temperature was assessed every 10 min during 1 h for physostigmine and 3 h for THA. Behavioral signs including tremor and gnawing were quantified at fixed times by a single experi menter who rated each animal on a scale of 0 (no effect) to + + + (maximum effect) ( Table 1) . As compared with the control group, a significant and long-lasting decrease in body temperature was ob served after THA 3, 5, and 10 mg/kg (analysis of variance, p < 0.001) and physostigmine 0.2 mg/kg (p < 0.05) and 0.5 mg/kg (p < 0.01) ( Table 1 ). The effect of THA on body temperature was dose de pendent: The highest dose of drug induced a signif icantly larger and longer effect than the lowest dose. Differences between 5 and 10 mg/kg were also significant during the last part of the observation period ( Fig. O. THA and physostigmine induced the same type of behavioral effects, but with different time courses (Table 1) . The intensity and duration of the effects were also dose dependent. On the basis of these observations, physostigmine (0.2 and 0.5 mg/ kg) and THA (5 and 10 mg/kg) were injected 10 and 50 min before [14C]DG, respectively.
Physiological parameters during [14C]DG experiment
Heart rate and mean arterial blood pressure did not change significantly during the LCGU measure ment (Table 2 ) except in the physostigmine-treated group (0.5 mg/kg) where a significant increase in arterial blood pressure occurred 15 min after [14C]DG, followed by a return to the baseline value at 45 min. Body temperature declined significantly after THA (10 mg/kg) and physostigmine (0.5 mg/ kg) (see Table 2 ). Plasma glucose concentration rose in all groups. Increases were larger after THA and physostigmine but not statistically significant as compared with controls. Since physiological parameters (as wel1 as LCGU) were similar in saline and HMB + AMB groups, these animals were subsequently pooled into one group (control group).
LCGU
Effects of THA. THA (5 mg/kg) significantly in creased LCGU in the insular, cingular, retrosple nial, and temporal cortices (Table 3 ) and in the thal amus, the lateral habenula, and the superior collic ulus (Tables 5 and 6). Enhanced LCGU was observed in 8 of the 43 regions studied. A higher dose of THA (l0 mg/kg) produced a larger meta bolic activation. LCGU increased in 19 of the 43 regions studied (Tables 3-6 ). In addition to the re gions where changes were observed after the 5-mg/ kg dose, LCGU increased in the parietal cortex (su perficial, granular, and deep layers), the medial sep tum, the dorsal (CA3) and ventral (CAl and CA3) hippocampus, the subiculum, the dentate gyrus, the basolateral amygdala, and the substantia nigra (pars compacta) (Fig. 2) . The effects of THA in the brain stem were limited to the superior col1iculus, whereas the cerebellum was unaffected (Table 6) . A consistent effect was found in the septohippocam pal system (Table 4 ) since LCGU increased in the medial septal area as well as in the dorsal and ven tral hippocampus and in the dentate gyrus. Surpris ingly, a decrease in LCGU was observed in the sub stantia innominata in spite of the fact that large in creases were observed in several cortical regions innervated by the basalocortical neurons.
Average hemispheric LCGU increased to 115% of control after 10 mg/kg of THA. However, the magnitude of the change depended on the brain re gion: Largest increases were found in the insular cortex (160%), ventral thalamus (147%), lateral habenula (155%) and superior colliculus (159%).
Effects of scopolamine + THA. Scopolamine suppressed the THA-induced increase in LCGU in 
10--12
Notice that the behavioral effects induced by the higher doses are similar for the two drugs but that their time courses differ. n = no. of rats.
a p < 0.05, b p < 0.01, 'p < 0.001, by analysis of variance.
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.. saline --0-tha 3 mg/kg (Tables 3-6) , including insular and cingular corti ces, medial septal area, thalamus, and brainstem nuclei. At 0. 5 mg/kg, the effects were more wide spread and stronger (22 of 43 regions). The average magnitude of the changes (113%) was similar to that observed after THA 10 mg/kg. Nevertheless, the topography of the affected regions was somewhat different. Physostigmine (5 mg/kg) increased LCGU in the globus pallidus, the preoptic magnocellular area (130%), five regions of the brain stem (average increase of 130%), and the cerebellum (interpositus nucleus, 122%) ( Fig. 3) . In contrast with THA, no effect was observed in the parietal cortex. The ef fects in the septohippocampal system were smaller than those induced by THA since the dorsal (CA3) Values are means ± SD. For abbreviations see the text. a p < 0.05, by analysis of variance. Values are mean LCGU ± SD. Statistical differences between controls and treated groups were examined by one-way analysis of variance followed by Scheffe's test: ap < 0.05; bp < 0.001: 'p < 0.01. and the ventral hippocampus as well as the dentate gyrus were unaffected.
DISCUSSION
The anticholinesterases THA and physostigmine increase LCGU in a substantial number of brain regions. The effects of THA are more consistent in the cortical and limbic areas, whereas physostig-mine is more active in the brain stem and cerebel lum.
Since there was a large overlap in the topography of THA and physostigmine effects, one cannot ex clude the possibility that the exceptions might be "false-positive," i.e., regions where a significant difference occurs by chance, only because of the large number of comparisons made. This explana tion seems, however, rather unlikely because the Values are means ± SD. THA, tetrahydroaminoacridine. Statistical differences were evaluated by analysis of variance: ap < 0.01; bp < 0.05; 'p < 0.001. Values are means ± SD. THA, tetrahydroaminoacridine. Statistical differences were evaluated by analysis of variance: "(decrease); bp < 0.05; cp < 0.001; d p < 0.01.
differences in LCG U were large even in those areas where only THA and physostigmine were active.
Regional distribution of cholinergic innervation and effects of THA
The fact that THA increases LCG U in defined cortical and subcortical areas suggests that it is not acting on the brain in a nonspecific manner. The study of the topography of the THA effects might give us some clues as to its mechanisms of action. It has been shown that THA has a complex pharma cological profile with both "cholinergic" and "non cholinergic" properties (see refs. in Dutar et ai., 1990) . If the effect of THA on LCGU is due to its cholinergic properties, one might expect to find cor relations between LCG U increase and the topogra phy of cholinergic markers such as choline acetyl transferase (ChAT) and AChE, cholinergic recep tors, and the density of cholinergic terminals or cholinergic neurons (Satoh et ai., 1983; Woolf, 1991) .
Obviously, the correlation with the density of cholinergic neurons is not excellent, since THA does not modify LCGU in certain regions contain-ing cholinergic neurons (magnocellular preoptic area, pedunculopontine tegmental and laterodorsal tegmental nuclei). On the other hand, THA in creases LCGU in certain areas receiving cholin ergic projections (parietal, temporal, cingular, insular, and retrosplenial cortices, basolateral amygdala, and lateral habenula), but not all of them (frontal, piriform, and entorhinal cortices, interpe duncular nucleus). Finally, areas receiving little (substantia nigra pars reticulata, central part of the globus pallidus) or virtually no (red nucleus, ante rior and ventral hypothalamic areas, raphe dorsalis) cholinergic innervation were not affected by THA.
The regional repartition of the effects of THA is not correlated to ChAT activity. Indeed, a number of regions where LCG U rose substantially after THA, such as the ventral hippocampus, the lateral habenula, and the basolateral amygdala, have a high level of ChAT activity (Hoover et ai., 1978) , whereas other "THA-sensitive" regions such as the parietal cortex, the ventral thalamus, and the nu cleus reticularis thalami have a rather low ChAT activity. In contrast, the effects of THA are related, at least in part, to the distribution of AChE activity ( Paxinos and Watson, 1982; Mash and Potter, 1986) . A large majority of the regions where THA increases LCGU (15 of 19 regions) have a high AChE activity. This correlation, however, is not perfect since it is not found in regions containing cholinergic interneurons (striatum), cholinergic mo tor neurons (facial nerve nucleus), or some regions containing cholinergic projection neurons (magno cellular preoptic area, pontomesencephalic nuclei).
Cholinergic receptor distribution and effects of THA
The THA-induced LCGU increase is not corre lated with M, receptor distribution. Regions with strong THA effects have either a low (medial sep tum, superior colliculus, thalamic nuclei) or a high (cingular and retrosplenial cortices) M, receptor density (Mash and Potter, 1986; Spencer et aI., 1986; Levey et aI. , 1991) . In contrast, there is an overlap between the distribution of M2 receptors (Mash and Potter, 1986) and the effect of THA. In deed, 14 of the 19 regions where THA increases LCGU are regions with a high density of M2 recep tors, whereas 10 of the 18 regions "insensitive" to THA have a low M2 receptor density. A few regions do not show this correlation (dorsal hippocampus, interpeduncular nucleus, pontomesencephalic cholinergic nuclei, central gray matter). It has been suggested that an interaction of THA with M2 re ceptors could play a role in its therapeutic effects. Perry et al. (1988) have shown that THA displaces muscarinic ligand binding in human cerebral cortex. This property may be therapeutically relevant by blocking the feedback inhibition of ACh release, via presynaptic M2 receptors. This hypothesis is also proposed by Adem et al. (1990) , who report that THA increases the release of ACh in cortical tissue slices from Alzheimer' s disease brains. However, no effect of THA on muscarinic receptors has been observed in the rat hippocampal slice (Dutar et aI. , 1990) . Pearce and Potter (1988) found that "clini cally effective" concentrations of THA inhibited AChE but were not likely to affect agonist interac tions with muscarinic receptors. It is therefore probable that the metabolic activation observed in regions receiving a cholinergic innervation is due mainly to the anticholinesterase activity of THA. However, we cannot exclude that the effects of THA might be partly mediated via interaction with muscarinic receptors. Another cholinergic agent, the muscarinic agonist arecoline, has been reported to increase LCG U in a large number of brain areas (Soncrant et aI. , 1985) . However, at low doses, arecoline has a selective effect on the hippocampus. It is likely that the unique sensitivity of the hippo- Values are means ± SD. Values were compared with controls by analysis of variance: ap < 0.05; bp < 0.001; 'p < 0.01; d (decrease). campus to arecoline results from a high density of muscarinic receptors in this structure.
Effects of THA on ion channels
LCaU is an index of regional energy consump tion, which is linked in turn to the functional (neu-J Cereb Blood Flow Metab, Vol. 13, No.5, 1993 ronal) activity. Some of the proposed mechanisms of action of THA could increase neuronal activity. For example, THA depolarizes neurons by blocking ion channels (Rogawski, 1987) . Excitatory effects on hippocampal neurons via an atropine-insensitive mechanism have been reported (Stevens and Cot- man, 1987). THA is also able to block various neu rotransmitter-generated inhibitory potassium con ductances, hence increasing the state of neuronal excitation (Halliwell and Grove, 1989; Dutar et al., 1990) . However, such nonspecific mechanisms should modify neuronal activity everywhere in the brain. In contrast, the present results show that THA induces a metabolic activation in a limited number of regions and suggest that the major effect of THA is due to its interaction with cholinergic mechanisms. This conclusion is also supported by the finding that the THA-induced increase in LCGU is almost completely reversed by scopolamine.
Effects of physostigmine
Physostigmine (2 mg/kg) increases LCGU in the neocortex, the hippocampus, the subiculum, and the substantia nigra . Scremin et al. (1988) reported that a low dose of physostigmine (0.05 mg/kg) did not modify LeGU, except in the superior colliculus. In the present ex periment, the effects of physostigmine and THA co incided in 14 regions studied. In addition, selective effects of physostigmine were observed in eight re gions. As anticipated, these regions either contain cholinergic projection neurons (magnocellular pre optic area, pontomesencephalic cholinergic nuclei, facial nerve nucleus) or receive an abundant cholin ergic innervation (interpeduncular nucleus, central gray matter). The correlation between the topogra phy of the physostigmine effects and that of M2 receptors is even better than for THA. LCGU in creases in the interpositus nucleus, a structure that receives few cholinergic fibers (Goldsmith and Van Der Kooy, 1988) but is involved in the control of muscular activity. The effect observed in the inter positus might be due to the muscular hyperactivity (tremors) induced by physostigmine rather than to a specific effect on cholinergic transmission.
The effects of physostigmine on LeGU are quan titatively similar to those of THA, although the dose of physostigmine was 20-fold smaller. Likewise, in vitro experiments have shown that physostigmine was to-fold more potent than THA in the hippocam pal slice preparation (Dutar et al., 1990) . The differ ence in efficacy of the drugs is probably due to the stronger anticholinesterase action of physostigmine (Becker and Giacobini, 1988; Hallak and Giacobini, 1989) .
The affinity of physostigmine for nicotinic recep tors (Nilsson et al., 1987; Nilsson-Haransson et al., 1990) and its ability to modulate ACh release differ from those of THA (Hallak and Giacobini, 1989) . These factors may explain, at least in part, the dif ferences found in the present study. In addition, variables such as differential drug distribution in the brain, accessibility of the sites of action, and spec ificity for different forms of AChE (Becker, 1991) could contribute to the regional selectivity of the drug effects.
Anticholinesterase-induced LCGU increase: Is there a relation with the therapeutic effects of the drugs?
To what extent an increase in LCGU is involved in the therapeutic effects of THA remains to be es tablished. It is interesting to note that the temporal and parietal cortices, which show the most consis tent LeGU alterations in Alzheimer's disease (Fos ter et al., 1984) , are among the regions that are the most "sensitive" to THA in the rat. Preliminary observations in one patient show that THA in creases glucose utilization in cerebral cortex and a few other structures (Nordberg et al., 1992) . Phy sostigmine and THA improve memory deficits in nucleus basalis-Iesioned rats (Murray and Fibiger, 1985; Kwo-On-Yuen et al., 1990) and in memory impaired aged monkeys (Bartus and Dean, 1988) . It would be interesting to know whether LeGU is modified in parallel with behavioral improvement in these animals. The metabolic activation observed in the septohippocampal system and in the cortex in the present experiment could result from an in creased neuronal activity in regions involved in cog nitive functions. Such an increase in LCGU might occur in Alzheimer patients receiving THA and par ticipate in the cognitive improvement.
